Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | BMP1 | P13497 | 3/20 | 0.44 |
| ▸ | MMP1 | P03956 | 2/20 | 0.44 |
| ▸ | MMP8 | P22894 | 2/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18938818 | 0.93 | SMN1; SMN2 (0.60) | SMN1; SMN2KMT2AMEN1RXFP1ALDH1A1 | |
| SCHEMBL16706700 | 0.93 | SMN1; SMN2 (0.44) | SMN1; SMN2KMT2AMEN1BMP1MMP1 | |
| SCHEMBL16706794 | 0.92 | SMN1; SMN2 (0.47) | SMN1; SMN2KMT2AMEN1BMP1RXFP1 | |
| SCHEMBL16706786 | 0.92 | SMN1; SMN2 (0.47) | SMN1; SMN2KMT2AMEN1BMP1MMP1 | |
| SCHEMBL16710137 | 0.91 | MAPT (0.52) | SMN1; SMN2KMT2AMEN1ALDH1A1HTT | |
| SCHEMBL18939712 | 0.90 | SMN1; SMN2 (0.55) | SMN1; SMN2KMT2AMEN1BMP1RXFP1 | |
| SCHEMBL18940991 | 0.89 | ALDH1A1 (0.45) | SMN1; SMN2KMT2AMEN1BMP1RXFP1 | |
| SCHEMBL16706662 | 0.89 | SMN1; SMN2 (0.45) | SMN1; SMN2KMT2AMEN1ALDH1A1TP53 | |
| SCHEMBL16710119 | 0.89 | SCD5 (0.46) | SMN1; SMN2KMT2AMEN1ALDH1A1HTT | |
| SCHEMBL16710040 | 0.89 | BMP1 (0.48) | SMN1; SMN2KMT2AMEN1BMP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951033-B2 | Tertiary amines for use in the treatment of cardiac disorders | UNIVERSITETET I OSLO (NO) | 2018-04-24 | — | — | US | disclosed |
| US-20170158657-A1 | TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS | UNIVERSITETET I OSLO (NO) | 2017-06-08 | — | — | US | disclosed |
| US-9556111-B2 | Tertiary amines for use in the treatment of cardiac disorders | UNIVERSITETET I OSLO (NO) | 2017-01-31 | — | — | US | disclosed |
| US-20150133510-A1 | TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS | UNIVERSITETET I OSLO (NO) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158657-A1 | TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS | TNNI3, TNNT2, MYLK2 | SMN1; SMN2 2862/4885KMT2A 976/4885MEN1 3450/4885 |
| US-20150133510-A1 | TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS | TNNI3, TNNT2, MYLK2 | SMN1; SMN2 3065/4885KMT2A 904/4885MEN1 3518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.